Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports positive breast cancer data for Afinitor

Novartis reports positive breast cancer data for Afinitor

6th July 2011

Novartis has reported positive data from a new study assessing its everolimus-based drug product Afinitor as a therapy for advanced breast cancer.

Data from the phase III Bolero-2 trial shows that the therapy was able to significantly extend progression-free survival when combined with exemestane, compared to placebo.

This meant that the drug was able to meet its primary endpoint in the clinical trial ahead of schedule, which led Novartis to call an early end to the study.

Herve Hoppenot, president of Novartis Oncology, said: "Based on these study results, this combination has the potential to extend the time until chemotherapy is needed for these patients."

Results from this trial will be used to support global regulatory submissions for the drug in this specification, which will be made before the end of 2011.

Everolimus is marketed by Novartis under different names for various specifications, with Europe's Committee for Medicinal Products for Human Use recommending the drug under the name Votubia as a tuberous sclerosis treatment last week.ADNFCR-8000103-ID-800612867-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.